| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myocardial Infarction | 317 | 2024 | 11718 | 7.800 |
Why?
|
| Thiazoles | 56 | 2022 | 1483 | 5.510 |
Why?
|
| Enoxaparin | 58 | 2012 | 377 | 5.290 |
Why?
|
| Angina, Unstable | 71 | 2013 | 926 | 5.240 |
Why?
|
| Atrial Fibrillation | 92 | 2024 | 5035 | 4.490 |
Why?
|
| Anticoagulants | 102 | 2024 | 4600 | 4.330 |
Why?
|
| Thrombolytic Therapy | 109 | 2018 | 2162 | 4.290 |
Why?
|
| Warfarin | 52 | 2024 | 1497 | 4.270 |
Why?
|
| Pyridines | 65 | 2022 | 2825 | 4.170 |
Why?
|
| Fibrinolytic Agents | 97 | 2015 | 2158 | 4.140 |
Why?
|
| Angioplasty, Balloon, Coronary | 82 | 2012 | 1873 | 3.400 |
Why?
|
| Heparin | 56 | 2012 | 1637 | 3.280 |
Why?
|
| Platelet Aggregation Inhibitors | 88 | 2021 | 3070 | 3.170 |
Why?
|
| American Heart Association | 34 | 2021 | 1057 | 2.720 |
Why?
|
| Hemorrhage | 72 | 2024 | 3461 | 2.520 |
Why?
|
| Myocardial Reperfusion | 26 | 2015 | 351 | 2.240 |
Why?
|
| Ticlopidine | 38 | 2016 | 899 | 2.220 |
Why?
|
| Thiophenes | 33 | 2014 | 589 | 2.220 |
Why?
|
| Electrocardiography | 113 | 2018 | 6442 | 1.990 |
Why?
|
| Embolism | 16 | 2023 | 408 | 1.950 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 33 | 2012 | 641 | 1.930 |
Why?
|
| Cardiology | 26 | 2018 | 1668 | 1.920 |
Why?
|
| Practice Guidelines as Topic | 36 | 2017 | 7281 | 1.900 |
Why?
|
| Stroke | 62 | 2024 | 9981 | 1.800 |
Why?
|
| Antithrombins | 12 | 2016 | 304 | 1.690 |
Why?
|
| Acute Coronary Syndrome | 41 | 2020 | 2337 | 1.640 |
Why?
|
| Cardiovascular Diseases | 60 | 2021 | 15159 | 1.590 |
Why?
|
| Piperazines | 34 | 2016 | 2488 | 1.540 |
Why?
|
| Heparin, Low-Molecular-Weight | 15 | 2008 | 339 | 1.430 |
Why?
|
| Troponin I | 16 | 2014 | 619 | 1.260 |
Why?
|
| Randomized Controlled Trials as Topic | 74 | 2024 | 9957 | 1.220 |
Why?
|
| Aspirin | 32 | 2021 | 3283 | 1.150 |
Why?
|
| Troponin T | 13 | 2017 | 754 | 1.130 |
Why?
|
| Double-Blind Method | 79 | 2021 | 12025 | 1.110 |
Why?
|
| Coronary Disease | 39 | 2008 | 6077 | 1.080 |
Why?
|
| Clinical Trials as Topic | 53 | 2016 | 7914 | 1.040 |
Why?
|
| Immunoglobulin Fab Fragments | 20 | 2005 | 482 | 1.010 |
Why?
|
| Myocardial Ischemia | 18 | 2020 | 2148 | 1.000 |
Why?
|
| Humans | 609 | 2024 | 744376 | 1.000 |
Why?
|
| Evidence-Based Medicine | 18 | 2015 | 3610 | 0.980 |
Why?
|
| Tissue Plasminogen Activator | 25 | 2009 | 1261 | 0.970 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 7 | 2020 | 257 | 0.970 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 10 | 2018 | 2282 | 0.930 |
Why?
|
| Heart Failure | 34 | 2023 | 10895 | 0.930 |
Why?
|
| Plasma | 3 | 2022 | 575 | 0.910 |
Why?
|
| Blood Coagulation | 12 | 2021 | 1127 | 0.910 |
Why?
|
| Anti-Arrhythmia Agents | 21 | 2017 | 789 | 0.870 |
Why?
|
| Treatment Outcome | 154 | 2024 | 63115 | 0.860 |
Why?
|
| Hirudin Therapy | 8 | 2002 | 43 | 0.860 |
Why?
|
| Creatine Kinase, MB Form | 7 | 2017 | 214 | 0.830 |
Why?
|
| Angina Pectoris | 23 | 2006 | 977 | 0.810 |
Why?
|
| Diffusion of Innovation | 3 | 2017 | 725 | 0.810 |
Why?
|
| Societies, Medical | 16 | 2018 | 3743 | 0.790 |
Why?
|
| Coronary Angiography | 58 | 2018 | 4576 | 0.780 |
Why?
|
| Emergency Medical Services | 14 | 2019 | 1917 | 0.770 |
Why?
|
| Risk Assessment | 66 | 2021 | 23336 | 0.760 |
Why?
|
| Remote Sensing Technology | 1 | 2021 | 90 | 0.740 |
Why?
|
| Aged | 246 | 2024 | 163284 | 0.740 |
Why?
|
| Middle Aged | 266 | 2022 | 213388 | 0.720 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2021 | 235 | 0.720 |
Why?
|
| Calcium Channel Blockers | 13 | 2014 | 692 | 0.710 |
Why?
|
| Coronary Circulation | 24 | 2010 | 1572 | 0.700 |
Why?
|
| Hirudins | 6 | 2003 | 183 | 0.690 |
Why?
|
| Thromboembolism | 11 | 2021 | 987 | 0.690 |
Why?
|
| Recombinant Proteins | 12 | 2016 | 6621 | 0.680 |
Why?
|
| Factor Xa | 6 | 2018 | 162 | 0.670 |
Why?
|
| Drug Therapy, Combination | 51 | 2013 | 6489 | 0.660 |
Why?
|
| Biomedical Research | 4 | 2015 | 3309 | 0.660 |
Why?
|
| Coronary Artery Disease | 15 | 2020 | 6486 | 0.660 |
Why?
|
| Information Dissemination | 3 | 2020 | 1099 | 0.660 |
Why?
|
| Magnesium | 6 | 2001 | 813 | 0.650 |
Why?
|
| Adrenergic beta-Antagonists | 26 | 2016 | 1240 | 0.640 |
Why?
|
| Male | 309 | 2024 | 350118 | 0.640 |
Why?
|
| Thrombin | 6 | 2005 | 598 | 0.640 |
Why?
|
| Coronary Artery Bypass | 20 | 2013 | 2288 | 0.640 |
Why?
|
| Naproxen | 1 | 2018 | 99 | 0.620 |
Why?
|
| Stents | 18 | 2014 | 3282 | 0.610 |
Why?
|
| Clinical Trials, Phase IV as Topic | 1 | 2017 | 27 | 0.610 |
Why?
|
| Propafenone | 7 | 1998 | 27 | 0.600 |
Why?
|
| Female | 301 | 2024 | 380200 | 0.590 |
Why?
|
| Purinergic P2 Receptor Antagonists | 8 | 2011 | 71 | 0.580 |
Why?
|
| Plasminogen Activators | 8 | 2009 | 209 | 0.570 |
Why?
|
| Transportation of Patients | 3 | 2013 | 185 | 0.570 |
Why?
|
| Biological Assay | 2 | 2017 | 652 | 0.570 |
Why?
|
| Perioperative Care | 13 | 2018 | 1002 | 0.560 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 11 | 2016 | 1516 | 0.560 |
Why?
|
| Health Status Indicators | 1 | 2021 | 970 | 0.540 |
Why?
|
| Blood Coagulation Factors | 2 | 2016 | 355 | 0.540 |
Why?
|
| Troponin | 11 | 2007 | 524 | 0.540 |
Why?
|
| Creatine Kinase | 16 | 2004 | 694 | 0.530 |
Why?
|
| Risk Factors | 98 | 2024 | 72295 | 0.530 |
Why?
|
| Patient Selection | 8 | 2022 | 4216 | 0.520 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2008 | 371 | 0.510 |
Why?
|
| Pharmacogenetics | 5 | 2020 | 674 | 0.500 |
Why?
|
| Anniversaries and Special Events | 2 | 2021 | 89 | 0.500 |
Why?
|
| United States | 76 | 2023 | 69869 | 0.490 |
Why?
|
| Administration, Oral | 17 | 2024 | 3914 | 0.490 |
Why?
|
| Time Factors | 71 | 2021 | 40077 | 0.480 |
Why?
|
| Cardiovascular Agents | 8 | 2013 | 850 | 0.480 |
Why?
|
| United States Public Health Service | 1 | 2014 | 31 | 0.480 |
Why?
|
| Sex Characteristics | 3 | 2021 | 2585 | 0.470 |
Why?
|
| Tyrosine | 9 | 2005 | 1462 | 0.470 |
Why?
|
| Food Industry | 1 | 2014 | 68 | 0.470 |
Why?
|
| Arrhythmias, Cardiac | 23 | 2012 | 2269 | 0.470 |
Why?
|
| Hemostatics | 1 | 2016 | 229 | 0.460 |
Why?
|
| Dose-Response Relationship, Drug | 32 | 2021 | 10943 | 0.460 |
Why?
|
| Digoxin | 6 | 2017 | 250 | 0.460 |
Why?
|
| Consumer Product Safety | 1 | 2014 | 122 | 0.450 |
Why?
|
| Guideline Adherence | 7 | 2019 | 2265 | 0.450 |
Why?
|
| Acute Disease | 30 | 2012 | 7147 | 0.440 |
Why?
|
| Syndrome | 29 | 2007 | 3252 | 0.440 |
Why?
|
| Heart Function Tests | 8 | 2008 | 328 | 0.440 |
Why?
|
| Drugs, Generic | 1 | 2017 | 421 | 0.430 |
Why?
|
| Recurrence | 31 | 2016 | 8340 | 0.430 |
Why?
|
| Access to Information | 1 | 2015 | 320 | 0.420 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 9 | 2020 | 362 | 0.420 |
Why?
|
| Catheter Ablation | 6 | 2022 | 2758 | 0.420 |
Why?
|
| Myocardial Revascularization | 19 | 2013 | 841 | 0.410 |
Why?
|
| Drug Substitution | 1 | 2014 | 281 | 0.400 |
Why?
|
| Meta-Analysis as Topic | 12 | 2003 | 1343 | 0.400 |
Why?
|
| Arthritis | 1 | 2017 | 659 | 0.400 |
Why?
|
| Antibodies, Monoclonal | 20 | 2005 | 9274 | 0.400 |
Why?
|
| Death, Sudden, Cardiac | 11 | 2018 | 1541 | 0.400 |
Why?
|
| Research Design | 14 | 2017 | 5986 | 0.400 |
Why?
|
| Intracranial Hemorrhages | 10 | 2021 | 855 | 0.400 |
Why?
|
| Hospitalization | 18 | 2022 | 10259 | 0.390 |
Why?
|
| Intraoperative Complications | 9 | 2012 | 1198 | 0.390 |
Why?
|
| Restaurants | 1 | 2014 | 236 | 0.390 |
Why?
|
| Coronary Care Units | 6 | 2004 | 214 | 0.380 |
Why?
|
| Program Development | 1 | 2017 | 1316 | 0.380 |
Why?
|
| Prognosis | 49 | 2023 | 29060 | 0.380 |
Why?
|
| Congresses as Topic | 2 | 2012 | 764 | 0.380 |
Why?
|
| Advisory Committees | 8 | 2014 | 775 | 0.380 |
Why?
|
| Health Status | 2 | 2021 | 4033 | 0.380 |
Why?
|
| Manuscripts as Topic | 1 | 2010 | 15 | 0.380 |
Why?
|
| Data Mining | 1 | 2015 | 537 | 0.370 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2016 | 941 | 0.370 |
Why?
|
| Sodium, Dietary | 1 | 2014 | 418 | 0.370 |
Why?
|
| Gastrointestinal Hemorrhage | 7 | 2018 | 1131 | 0.370 |
Why?
|
| Pharmaceutical Preparations | 2 | 2012 | 1070 | 0.360 |
Why?
|
| Medicine | 3 | 2022 | 946 | 0.360 |
Why?
|
| Blood Flow Velocity | 7 | 2005 | 1423 | 0.360 |
Why?
|
| Thrombosis | 13 | 2013 | 2968 | 0.350 |
Why?
|
| Peptide Fragments | 7 | 2023 | 5096 | 0.350 |
Why?
|
| Health Behavior | 2 | 2021 | 2635 | 0.350 |
Why?
|
| Pacemaker, Artificial | 9 | 2019 | 816 | 0.350 |
Why?
|
| Nifedipine | 10 | 1987 | 227 | 0.350 |
Why?
|
| Confidentiality | 1 | 2014 | 612 | 0.340 |
Why?
|
| Government Regulation | 1 | 2014 | 522 | 0.340 |
Why?
|
| Electric Countershock | 11 | 2006 | 534 | 0.340 |
Why?
|
| Biopsy, Needle | 1 | 2014 | 1641 | 0.340 |
Why?
|
| Drug Therapy | 2 | 2021 | 497 | 0.340 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 5 | 2013 | 153 | 0.340 |
Why?
|
| Sodium | 2 | 2014 | 1622 | 0.330 |
Why?
|
| Patient Care | 1 | 2014 | 640 | 0.330 |
Why?
|
| Bundle-Branch Block | 2 | 2010 | 270 | 0.330 |
Why?
|
| Coronary Thrombosis | 5 | 2009 | 495 | 0.330 |
Why?
|
| Digitalis Glycosides | 7 | 2016 | 47 | 0.330 |
Why?
|
| Heart Arrest | 7 | 2008 | 1470 | 0.330 |
Why?
|
| Myocytes, Cardiac | 1 | 2017 | 1629 | 0.320 |
Why?
|
| Risk Reduction Behavior | 3 | 2014 | 1125 | 0.320 |
Why?
|
| Food Supply | 1 | 2014 | 524 | 0.320 |
Why?
|
| Stroke Volume | 13 | 2023 | 5006 | 0.320 |
Why?
|
| Atrial Flutter | 7 | 2003 | 263 | 0.320 |
Why?
|
| Medical Informatics | 1 | 2015 | 745 | 0.310 |
Why?
|
| Coronary Stenosis | 5 | 2010 | 834 | 0.310 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2014 | 816 | 0.310 |
Why?
|
| Drug Administration Schedule | 16 | 2019 | 4933 | 0.300 |
Why?
|
| Combined Modality Therapy | 20 | 2014 | 8642 | 0.300 |
Why?
|
| Ventricular Fibrillation | 6 | 2006 | 538 | 0.300 |
Why?
|
| Magnesium Sulfate | 4 | 2004 | 68 | 0.290 |
Why?
|
| Thienopyridines | 3 | 2010 | 12 | 0.290 |
Why?
|
| Quality Improvement | 3 | 2019 | 3749 | 0.290 |
Why?
|
| Forecasting | 7 | 2016 | 2951 | 0.290 |
Why?
|
| Natriuretic Peptide, Brain | 8 | 2023 | 1572 | 0.290 |
Why?
|
| Sleep | 2 | 2023 | 4623 | 0.280 |
Why?
|
| Medication Adherence | 6 | 2023 | 2063 | 0.280 |
Why?
|
| Data Collection | 4 | 2014 | 3339 | 0.280 |
Why?
|
| Proton Pump Inhibitors | 5 | 2013 | 526 | 0.280 |
Why?
|
| Heart Valve Prosthesis Implantation | 3 | 2017 | 1537 | 0.280 |
Why?
|
| Proportional Hazards Models | 18 | 2019 | 12356 | 0.270 |
Why?
|
| Heart Rupture, Post-Infarction | 3 | 2003 | 49 | 0.270 |
Why?
|
| Cooperative Behavior | 5 | 2020 | 1504 | 0.270 |
Why?
|
| Pandemics | 4 | 2022 | 8386 | 0.270 |
Why?
|
| Atrial Function, Left | 2 | 2019 | 173 | 0.270 |
Why?
|
| Leadership | 1 | 2015 | 1357 | 0.270 |
Why?
|
| Tachycardia | 8 | 2001 | 619 | 0.270 |
Why?
|
| Angioplasty, Balloon | 3 | 2004 | 653 | 0.260 |
Why?
|
| Registries | 13 | 2019 | 8091 | 0.260 |
Why?
|
| Infusions, Intravenous | 12 | 2009 | 2274 | 0.260 |
Why?
|
| Secondary Prevention | 13 | 2021 | 1530 | 0.260 |
Why?
|
| Myoglobin | 8 | 2002 | 160 | 0.260 |
Why?
|
| International Cooperation | 7 | 2016 | 1420 | 0.260 |
Why?
|
| Isoenzymes | 13 | 2004 | 1728 | 0.260 |
Why?
|
| Odds Ratio | 23 | 2022 | 9849 | 0.260 |
Why?
|
| Partial Thromboplastin Time | 7 | 2012 | 206 | 0.260 |
Why?
|
| Stem Cell Transplantation | 1 | 2014 | 1620 | 0.260 |
Why?
|
| Predictive Value of Tests | 27 | 2021 | 15078 | 0.250 |
Why?
|
| Verapamil | 7 | 1991 | 244 | 0.250 |
Why?
|
| Smoking | 7 | 2014 | 8987 | 0.250 |
Why?
|
| Professional Practice | 2 | 2006 | 326 | 0.250 |
Why?
|
| Clinical Trials, Phase III as Topic | 8 | 2020 | 841 | 0.250 |
Why?
|
| Multicenter Studies as Topic | 11 | 2009 | 1677 | 0.250 |
Why?
|
| Insurance, Pharmaceutical Services | 3 | 2013 | 336 | 0.250 |
Why?
|
| Fatty Acids, Omega-3 | 3 | 2019 | 1344 | 0.240 |
Why?
|
| Echocardiography | 12 | 2019 | 5099 | 0.240 |
Why?
|
| Follow-Up Studies | 40 | 2021 | 39052 | 0.240 |
Why?
|
| Diabetes Mellitus | 7 | 2021 | 5749 | 0.240 |
Why?
|
| Public Health | 3 | 2014 | 2602 | 0.240 |
Why?
|
| Drug Interactions | 13 | 2013 | 1460 | 0.240 |
Why?
|
| Conservation of Natural Resources | 3 | 2014 | 204 | 0.240 |
Why?
|
| Platelet Aggregation | 8 | 2011 | 798 | 0.240 |
Why?
|
| Sotalol | 3 | 1995 | 49 | 0.240 |
Why?
|
| International Normalized Ratio | 4 | 2020 | 367 | 0.230 |
Why?
|
| Risk | 13 | 2019 | 9688 | 0.230 |
Why?
|
| Disease Management | 13 | 2016 | 2460 | 0.230 |
Why?
|
| Survival Rate | 17 | 2019 | 12788 | 0.230 |
Why?
|
| Survival Analysis | 23 | 2019 | 10252 | 0.230 |
Why?
|
| Heart Rate | 21 | 2016 | 4091 | 0.230 |
Why?
|
| Fibrinolysis | 2 | 2010 | 322 | 0.230 |
Why?
|
| Point-of-Care Systems | 7 | 2007 | 1178 | 0.230 |
Why?
|
| Multivariate Analysis | 21 | 2016 | 12244 | 0.230 |
Why?
|
| Thromboplastin | 1 | 2005 | 291 | 0.220 |
Why?
|
| Surgical Procedures, Operative | 7 | 2008 | 1876 | 0.220 |
Why?
|
| Heart Conduction System | 14 | 2004 | 1047 | 0.220 |
Why?
|
| Health Policy | 3 | 2014 | 2661 | 0.220 |
Why?
|
| Vascular Patency | 10 | 2010 | 887 | 0.220 |
Why?
|
| Diltiazem | 5 | 2014 | 133 | 0.220 |
Why?
|
| Cardiac Pacing, Artificial | 5 | 2003 | 845 | 0.220 |
Why?
|
| Atherectomy, Coronary | 1 | 2003 | 148 | 0.220 |
Why?
|
| United States Food and Drug Administration | 4 | 2015 | 1584 | 0.220 |
Why?
|
| Cost of Illness | 1 | 2012 | 1860 | 0.220 |
Why?
|
| Comorbidity | 16 | 2022 | 10388 | 0.220 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2014 | 1736 | 0.220 |
Why?
|
| Periodicals as Topic | 1 | 2014 | 1431 | 0.220 |
Why?
|
| Decision Support Techniques | 1 | 2013 | 1956 | 0.210 |
Why?
|
| Europe | 8 | 2018 | 3339 | 0.210 |
Why?
|
| Immunization, Passive | 2 | 2022 | 623 | 0.210 |
Why?
|
| Heart Rupture | 3 | 1999 | 23 | 0.210 |
Why?
|
| Emergency Service, Hospital | 8 | 2013 | 7658 | 0.210 |
Why?
|
| Evidence-Based Practice | 2 | 2017 | 501 | 0.210 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 7 | 2023 | 3255 | 0.210 |
Why?
|
| Aortic Valve | 1 | 2012 | 1924 | 0.210 |
Why?
|
| Databases, Factual | 4 | 2015 | 7730 | 0.210 |
Why?
|
| Ventricular Remodeling | 3 | 2019 | 1223 | 0.200 |
Why?
|
| Smoking Cessation | 1 | 2014 | 2071 | 0.200 |
Why?
|
| Severity of Illness Index | 20 | 2022 | 15535 | 0.200 |
Why?
|
| Controlled Clinical Trials as Topic | 2 | 2001 | 187 | 0.200 |
Why?
|
| Mibefradil | 1 | 2000 | 6 | 0.190 |
Why?
|
| Hypertension | 13 | 2023 | 8479 | 0.190 |
Why?
|
| Prescription Drugs | 2 | 2021 | 595 | 0.190 |
Why?
|
| Liver Diseases | 2 | 2019 | 1253 | 0.190 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2021 | 68 | 0.190 |
Why?
|
| Nitroglycerin | 8 | 1998 | 325 | 0.190 |
Why?
|
| Early Diagnosis | 3 | 2017 | 1184 | 0.190 |
Why?
|
| Adult | 74 | 2021 | 214056 | 0.190 |
Why?
|
| Tachycardia, Supraventricular | 2 | 2003 | 263 | 0.190 |
Why?
|
| Amiodarone | 3 | 2015 | 212 | 0.190 |
Why?
|
| Policy Making | 2 | 2016 | 554 | 0.180 |
Why?
|
| Health Services Needs and Demand | 1 | 2008 | 1410 | 0.180 |
Why?
|
| Eye Hemorrhage | 1 | 2020 | 19 | 0.180 |
Why?
|
| Creatinine | 8 | 2016 | 1919 | 0.180 |
Why?
|
| Incidence | 24 | 2021 | 20950 | 0.180 |
Why?
|
| Insect Proteins | 1 | 2001 | 258 | 0.180 |
Why?
|
| Sleep Apnea, Obstructive | 2 | 2023 | 1813 | 0.180 |
Why?
|
| Defibrillators, Implantable | 4 | 2019 | 1440 | 0.180 |
Why?
|
| Thrombocytopenia | 1 | 2007 | 1178 | 0.170 |
Why?
|
| Histamine H2 Antagonists | 2 | 2010 | 165 | 0.170 |
Why?
|
| Fatty Acid Desaturases | 1 | 2019 | 102 | 0.170 |
Why?
|
| Drug Costs | 4 | 2017 | 1105 | 0.170 |
Why?
|
| Logistic Models | 20 | 2019 | 13409 | 0.170 |
Why?
|
| Half-Life | 4 | 2018 | 661 | 0.170 |
Why?
|
| Heart Diseases | 9 | 2008 | 2789 | 0.170 |
Why?
|
| Sinoatrial Node | 6 | 1995 | 101 | 0.170 |
Why?
|
| World Health Organization | 2 | 2022 | 1318 | 0.170 |
Why?
|
| Emergency Medicine | 1 | 2008 | 1205 | 0.170 |
Why?
|
| Civil Defense | 1 | 2020 | 109 | 0.170 |
Why?
|
| Heart Atria | 5 | 2019 | 1356 | 0.170 |
Why?
|
| Propranolol | 4 | 1993 | 502 | 0.170 |
Why?
|
| Education, Medical | 1 | 2011 | 1722 | 0.170 |
Why?
|
| Peripheral Vascular Diseases | 3 | 2006 | 550 | 0.160 |
Why?
|
| Heart Valve Diseases | 3 | 2017 | 1074 | 0.160 |
Why?
|
| Patient Discharge | 5 | 2013 | 3318 | 0.160 |
Why?
|
| Pericardium | 2 | 2002 | 667 | 0.160 |
Why?
|
| Peptides | 6 | 2009 | 4410 | 0.160 |
Why?
|
| Prospective Studies | 34 | 2023 | 53291 | 0.160 |
Why?
|
| Cross-Over Studies | 5 | 2019 | 2029 | 0.160 |
Why?
|
| Family Practice | 2 | 1999 | 516 | 0.160 |
Why?
|
| Immunoassay | 5 | 2008 | 752 | 0.160 |
Why?
|
| Internationality | 3 | 2016 | 1002 | 0.160 |
Why?
|
| Lidocaine | 7 | 1996 | 544 | 0.160 |
Why?
|
| Ibuprofen | 2 | 2018 | 236 | 0.160 |
Why?
|
| Injections, Intravenous | 5 | 2009 | 1420 | 0.160 |
Why?
|
| Confidence Intervals | 6 | 2010 | 2971 | 0.150 |
Why?
|
| Quinidine | 4 | 1992 | 57 | 0.150 |
Why?
|
| Drug Evaluation | 3 | 1996 | 647 | 0.150 |
Why?
|
| Cause of Death | 10 | 2019 | 3582 | 0.150 |
Why?
|
| Aged, 80 and over | 31 | 2021 | 57776 | 0.150 |
Why?
|
| Data Interpretation, Statistical | 7 | 2014 | 2716 | 0.150 |
Why?
|
| Terminology as Topic | 3 | 2012 | 1547 | 0.140 |
Why?
|
| Physicians | 4 | 2022 | 4567 | 0.140 |
Why?
|
| Arginine | 2 | 2021 | 944 | 0.140 |
Why?
|
| Kaplan-Meier Estimate | 10 | 2017 | 6539 | 0.140 |
Why?
|
| Sensitivity and Specificity | 9 | 2017 | 14723 | 0.140 |
Why?
|
| Hospital Mortality | 12 | 2019 | 5316 | 0.140 |
Why?
|
| Exercise Test | 10 | 2006 | 2073 | 0.140 |
Why?
|
| Metformin | 1 | 2023 | 836 | 0.140 |
Why?
|
| Age Factors | 12 | 2016 | 18373 | 0.140 |
Why?
|
| Coronary Vessels | 10 | 2005 | 3107 | 0.140 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2017 | 288 | 0.140 |
Why?
|
| Aryldialkylphosphatase | 1 | 2016 | 63 | 0.140 |
Why?
|
| Intention to Treat Analysis | 1 | 2017 | 426 | 0.140 |
Why?
|
| Interinstitutional Relations | 2 | 2014 | 241 | 0.140 |
Why?
|
| Factor VIIa | 1 | 2016 | 101 | 0.130 |
Why?
|
| Streptokinase | 4 | 2009 | 188 | 0.130 |
Why?
|
| Regression Analysis | 6 | 2005 | 6459 | 0.130 |
Why?
|
| Consensus | 5 | 2015 | 2960 | 0.130 |
Why?
|
| Aortic Valve Stenosis | 4 | 2024 | 1965 | 0.130 |
Why?
|
| Sex Factors | 11 | 2021 | 10400 | 0.130 |
Why?
|
| Device Removal | 2 | 2019 | 656 | 0.130 |
Why?
|
| Prosthesis Implantation | 2 | 2019 | 642 | 0.130 |
Why?
|
| Necrosis | 4 | 2008 | 1643 | 0.130 |
Why?
|
| Goals | 3 | 2015 | 707 | 0.130 |
Why?
|
| Propanolamines | 4 | 1988 | 167 | 0.130 |
Why?
|
| Quality Assurance, Health Care | 8 | 2012 | 2212 | 0.130 |
Why?
|
| Prothrombin Time | 1 | 2014 | 119 | 0.120 |
Why?
|
| Clinical Enzyme Tests | 3 | 1999 | 115 | 0.120 |
Why?
|
| Population | 1 | 2014 | 142 | 0.120 |
Why?
|
| Decision Trees | 3 | 2007 | 506 | 0.120 |
Why?
|
| Myocardium | 5 | 2008 | 4772 | 0.120 |
Why?
|
| Ventricular Function, Left | 5 | 2019 | 3666 | 0.120 |
Why?
|
| Kidney Diseases | 6 | 2012 | 2148 | 0.120 |
Why?
|
| Bayes Theorem | 2 | 2022 | 2308 | 0.120 |
Why?
|
| Reproducibility of Results | 7 | 2022 | 19905 | 0.120 |
Why?
|
| Receptors, Purinergic P2Y12 | 4 | 2011 | 132 | 0.120 |
Why?
|
| Respiration, Artificial | 2 | 2022 | 2569 | 0.120 |
Why?
|
| Health Promotion | 3 | 2015 | 2205 | 0.120 |
Why?
|
| Heart Ventricles | 12 | 2016 | 3817 | 0.120 |
Why?
|
| Life Tables | 4 | 2004 | 370 | 0.120 |
Why?
|
| Length of Stay | 4 | 2005 | 6311 | 0.120 |
Why?
|
| Hypotension | 5 | 1989 | 884 | 0.110 |
Why?
|
| Patient Education as Topic | 5 | 2012 | 2278 | 0.110 |
Why?
|
| Hemodynamics | 13 | 2001 | 4196 | 0.110 |
Why?
|
| Hyperlipidemias | 2 | 2014 | 789 | 0.110 |
Why?
|
| Clinical Chemistry Tests | 1 | 2013 | 61 | 0.110 |
Why?
|
| Withholding Treatment | 1 | 2018 | 599 | 0.110 |
Why?
|
| Pyridones | 2 | 2016 | 712 | 0.110 |
Why?
|
| Kidney | 4 | 2016 | 7184 | 0.110 |
Why?
|
| Cardiomyopathy, Hypertrophic | 4 | 2014 | 1265 | 0.110 |
Why?
|
| Patient Compliance | 3 | 2008 | 2685 | 0.110 |
Why?
|
| Obesity | 7 | 2019 | 12745 | 0.110 |
Why?
|
| Prodrugs | 3 | 2009 | 268 | 0.110 |
Why?
|
| Therapeutic Equivalency | 3 | 2003 | 141 | 0.110 |
Why?
|
| Genotype | 6 | 2020 | 12952 | 0.110 |
Why?
|
| Perhexiline | 2 | 1990 | 5 | 0.110 |
Why?
|
| Cardiology Service, Hospital | 2 | 2012 | 246 | 0.110 |
Why?
|
| Ventricular Function | 3 | 2006 | 415 | 0.110 |
Why?
|
| Drug Discovery | 1 | 2020 | 1058 | 0.110 |
Why?
|
| Bioprosthesis | 1 | 2017 | 597 | 0.110 |
Why?
|
| Injections, Subcutaneous | 3 | 2010 | 667 | 0.100 |
Why?
|
| Renal Insufficiency | 2 | 2009 | 804 | 0.100 |
Why?
|
| Myocardial Contraction | 7 | 1999 | 1579 | 0.100 |
Why?
|
| Clinical Alarms | 1 | 2012 | 52 | 0.100 |
Why?
|
| Cost-Benefit Analysis | 8 | 2015 | 5390 | 0.100 |
Why?
|
| Marfan Syndrome | 1 | 1994 | 240 | 0.100 |
Why?
|
| Acetylcysteine | 3 | 1988 | 271 | 0.100 |
Why?
|
| Drug Utilization | 4 | 2011 | 1183 | 0.100 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2016 | 339 | 0.100 |
Why?
|
| Regional Health Planning | 1 | 2012 | 97 | 0.100 |
Why?
|
| Sarcomeres | 1 | 2014 | 374 | 0.100 |
Why?
|
| Tachycardia, Ventricular | 2 | 2006 | 1273 | 0.100 |
Why?
|
| Peripheral Arterial Disease | 1 | 2022 | 1188 | 0.100 |
Why?
|
| Gastrointestinal Diseases | 3 | 2010 | 1170 | 0.100 |
Why?
|
| Metoprolol | 2 | 1989 | 93 | 0.100 |
Why?
|
| Angina Pectoris, Variant | 4 | 1983 | 55 | 0.100 |
Why?
|
| Electrodes, Implanted | 3 | 2012 | 824 | 0.100 |
Why?
|
| Body Weight | 6 | 2024 | 4671 | 0.100 |
Why?
|
| Nadroparin | 2 | 2001 | 3 | 0.100 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2012 | 287 | 0.100 |
Why?
|
| Radionuclide Imaging | 7 | 2006 | 2031 | 0.090 |
Why?
|
| Atrial Natriuretic Factor | 2 | 2002 | 393 | 0.090 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2013 | 923 | 0.090 |
Why?
|
| Dalteparin | 2 | 2001 | 42 | 0.090 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2012 | 281 | 0.090 |
Why?
|
| Health Services Accessibility | 3 | 2017 | 5135 | 0.090 |
Why?
|
| Hyperkalemia | 1 | 2012 | 218 | 0.090 |
Why?
|
| Insurance Coverage | 3 | 2013 | 1900 | 0.090 |
Why?
|
| Heterozygote | 2 | 2014 | 2804 | 0.090 |
Why?
|
| Decision Making | 3 | 2014 | 3888 | 0.090 |
Why?
|
| Ambulances | 2 | 2007 | 95 | 0.090 |
Why?
|
| Drug Approval | 2 | 2015 | 742 | 0.090 |
Why?
|
| Cardiac Output, Low | 3 | 2006 | 195 | 0.090 |
Why?
|
| Cyclic N-Oxides | 1 | 2009 | 78 | 0.090 |
Why?
|
| Life Style | 1 | 2021 | 3835 | 0.090 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 950 | 0.090 |
Why?
|
| Diastole | 4 | 2014 | 791 | 0.090 |
Why?
|
| Heart Valve Prosthesis | 2 | 2017 | 1490 | 0.090 |
Why?
|
| Cardiotonic Agents | 2 | 2016 | 535 | 0.090 |
Why?
|
| Cohort Studies | 12 | 2019 | 40558 | 0.090 |
Why?
|
| Glomerular Filtration Rate | 2 | 2009 | 2166 | 0.080 |
Why?
|
| Physical Exertion | 3 | 1987 | 695 | 0.080 |
Why?
|
| Retrospective Studies | 25 | 2023 | 77459 | 0.080 |
Why?
|
| Protein Precursors | 3 | 2006 | 1154 | 0.080 |
Why?
|
| Physicians, Family | 1 | 2011 | 345 | 0.080 |
Why?
|
| Safety | 4 | 2018 | 1186 | 0.080 |
Why?
|
| Electroencephalography | 1 | 2004 | 6150 | 0.080 |
Why?
|
| Thrombophilia | 2 | 2016 | 305 | 0.080 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 2213 | 0.080 |
Why?
|
| Computational Biology | 1 | 2021 | 3519 | 0.080 |
Why?
|
| Occupational Health | 1 | 2015 | 808 | 0.080 |
Why?
|
| Accidental Falls | 1 | 2016 | 1062 | 0.080 |
Why?
|
| RNA, Untranslated | 1 | 2012 | 453 | 0.080 |
Why?
|
| Cardiovascular System | 2 | 2014 | 831 | 0.080 |
Why?
|
| Anesthesia | 7 | 2008 | 1560 | 0.080 |
Why?
|
| Antiviral Agents | 1 | 2020 | 2987 | 0.080 |
Why?
|
| Proteomics | 1 | 2021 | 3638 | 0.080 |
Why?
|
| von Willebrand Factor | 2 | 2005 | 669 | 0.080 |
Why?
|
| Genome-Wide Association Study | 2 | 2020 | 12262 | 0.080 |
Why?
|
| Models, Economic | 2 | 2012 | 712 | 0.080 |
Why?
|
| Patient Transfer | 1 | 2015 | 762 | 0.080 |
Why?
|
| Aortic Diseases | 1 | 1994 | 743 | 0.080 |
Why?
|
| Benzofurans | 2 | 1986 | 140 | 0.080 |
Why?
|
| Diagnosis, Differential | 10 | 2012 | 12961 | 0.080 |
Why?
|
| Isosorbide Dinitrate | 1 | 1987 | 34 | 0.080 |
Why?
|
| History, 21st Century | 1 | 2014 | 1534 | 0.080 |
Why?
|
| Platelet Activation | 2 | 2010 | 674 | 0.080 |
Why?
|
| Cardiac Glycosides | 1 | 1987 | 30 | 0.080 |
Why?
|
| Monitoring, Physiologic | 5 | 2002 | 1739 | 0.080 |
Why?
|
| Cost Sharing | 2 | 2008 | 407 | 0.080 |
Why?
|
| Phenothiazines | 1 | 1987 | 63 | 0.070 |
Why?
|
| Prostaglandin Antagonists | 1 | 2007 | 30 | 0.070 |
Why?
|
| Emergencies | 5 | 2001 | 1170 | 0.070 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 681 | 0.070 |
Why?
|
| Duty to Warn | 1 | 2007 | 30 | 0.070 |
Why?
|
| Algorithms | 7 | 2022 | 13882 | 0.070 |
Why?
|
| Human Experimentation | 2 | 2004 | 127 | 0.070 |
Why?
|
| Long-Term Care | 5 | 2008 | 607 | 0.070 |
Why?
|
| Fibrin | 1 | 2009 | 506 | 0.070 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2009 | 419 | 0.070 |
Why?
|
| Sympatholytics | 1 | 2006 | 83 | 0.070 |
Why?
|
| Mutation, Missense | 1 | 2016 | 2566 | 0.070 |
Why?
|
| Chi-Square Distribution | 7 | 2010 | 3508 | 0.070 |
Why?
|
| Critical Pathways | 2 | 2022 | 476 | 0.070 |
Why?
|
| Bradycardia | 1 | 1988 | 307 | 0.070 |
Why?
|
| Canada | 3 | 2005 | 2065 | 0.070 |
Why?
|
| Cardiac Surgical Procedures | 4 | 2018 | 3537 | 0.070 |
Why?
|
| History, 20th Century | 2 | 2014 | 2740 | 0.070 |
Why?
|
| Ventricular Dysfunction, Left | 6 | 2004 | 2073 | 0.070 |
Why?
|
| Pyrazoles | 1 | 2016 | 1972 | 0.070 |
Why?
|
| Young Adult | 6 | 2021 | 56434 | 0.070 |
Why?
|
| Laboratories | 1 | 2009 | 463 | 0.070 |
Why?
|
| Myocardial Reperfusion Injury | 2 | 2001 | 476 | 0.070 |
Why?
|
| Ventricular Dysfunction | 1 | 2006 | 143 | 0.070 |
Why?
|
| Endpoint Determination | 5 | 2009 | 601 | 0.070 |
Why?
|
| Pulsatile Flow | 2 | 2004 | 332 | 0.070 |
Why?
|
| Radiography | 5 | 2006 | 7023 | 0.070 |
Why?
|
| Helicobacter pylori | 1 | 2008 | 383 | 0.060 |
Why?
|
| Wolff-Parkinson-White Syndrome | 2 | 2001 | 117 | 0.060 |
Why?
|
| Conflict of Interest | 3 | 2004 | 544 | 0.060 |
Why?
|
| Heart Defects, Congenital | 4 | 2008 | 4583 | 0.060 |
Why?
|
| Helicobacter Infections | 1 | 2008 | 387 | 0.060 |
Why?
|
| Benzazepines | 2 | 1985 | 326 | 0.060 |
Why?
|
| Nitrous Oxide | 1 | 1985 | 176 | 0.060 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2007 | 320 | 0.060 |
Why?
|
| Chronic Disease | 9 | 2006 | 9145 | 0.060 |
Why?
|
| Angioplasty | 2 | 2004 | 364 | 0.060 |
Why?
|
| Drug Labeling | 1 | 2007 | 233 | 0.060 |
Why?
|
| Hemoglobins | 2 | 2009 | 1532 | 0.060 |
Why?
|
| Models, Statistical | 5 | 2012 | 5101 | 0.060 |
Why?
|
| Antifibrinolytic Agents | 1 | 2007 | 254 | 0.060 |
Why?
|
| Photons | 1 | 2008 | 588 | 0.060 |
Why?
|
| Thromboxane A2 | 1 | 2004 | 93 | 0.060 |
Why?
|
| Brain Ischemia | 2 | 2016 | 3265 | 0.060 |
Why?
|
| Evidence-Based Emergency Medicine | 1 | 2004 | 10 | 0.060 |
Why?
|
| Ethics, Professional | 1 | 2004 | 102 | 0.060 |
Why?
|
| Circadian Rhythm | 2 | 2013 | 2624 | 0.060 |
Why?
|
| Premedication | 1 | 2005 | 258 | 0.060 |
Why?
|
| Quantitative Trait Loci | 1 | 2012 | 2019 | 0.060 |
Why?
|
| Models, Biological | 2 | 2012 | 9584 | 0.060 |
Why?
|
| Adolescent | 16 | 2014 | 85784 | 0.060 |
Why?
|
| Treatment Failure | 5 | 2006 | 2618 | 0.060 |
Why?
|
| Microfilament Proteins | 1 | 2009 | 1152 | 0.060 |
Why?
|
| Blood Pressure | 9 | 2012 | 8551 | 0.060 |
Why?
|
| Membrane Proteins | 3 | 2005 | 7882 | 0.060 |
Why?
|
| Medicare Part D | 1 | 2008 | 328 | 0.060 |
Why?
|
| Telephone | 1 | 1986 | 617 | 0.060 |
Why?
|
| Cryotherapy | 1 | 2004 | 155 | 0.060 |
Why?
|
| Nitrates | 2 | 2000 | 265 | 0.050 |
Why?
|
| Time | 2 | 2003 | 542 | 0.050 |
Why?
|
| Cobalt | 1 | 2003 | 158 | 0.050 |
Why?
|
| Cell Adhesion Molecules | 1 | 2009 | 1602 | 0.050 |
Why?
|
| Health Expenditures | 2 | 2012 | 2349 | 0.050 |
Why?
|
| Edema | 1 | 2007 | 789 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2004 | 629 | 0.050 |
Why?
|
| Diabetes Complications | 2 | 2007 | 1359 | 0.050 |
Why?
|
| Computer Simulation | 2 | 2012 | 6194 | 0.050 |
Why?
|
| C-Reactive Protein | 4 | 2004 | 3778 | 0.050 |
Why?
|
| Blood Platelets | 2 | 2011 | 2509 | 0.050 |
Why?
|
| Statistics as Topic | 4 | 2004 | 2373 | 0.050 |
Why?
|
| Cost Savings | 1 | 2008 | 925 | 0.050 |
Why?
|
| ROC Curve | 5 | 2019 | 3527 | 0.050 |
Why?
|
| Ethics, Medical | 2 | 2004 | 792 | 0.050 |
Why?
|
| Disease-Free Survival | 3 | 2008 | 6896 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3135 | 0.050 |
Why?
|
| Natriuresis | 1 | 2002 | 124 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3242 | 0.050 |
Why?
|
| Mathematics | 1 | 2003 | 728 | 0.050 |
Why?
|
| Whole Blood Coagulation Time | 1 | 2001 | 30 | 0.050 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2023 | 176 | 0.050 |
Why?
|
| Animals | 17 | 2020 | 168770 | 0.050 |
Why?
|
| Blood Coagulation Tests | 1 | 2003 | 263 | 0.050 |
Why?
|
| Guidelines as Topic | 1 | 2008 | 1405 | 0.050 |
Why?
|
| Models, Cardiovascular | 2 | 2006 | 996 | 0.050 |
Why?
|
| Mesenteric Arteries | 3 | 2006 | 183 | 0.050 |
Why?
|
| Single-Blind Method | 3 | 2016 | 1591 | 0.050 |
Why?
|
| Salivary Proteins and Peptides | 1 | 2001 | 53 | 0.050 |
Why?
|
| Triage | 3 | 2009 | 977 | 0.050 |
Why?
|
| Gait Ataxia | 1 | 2001 | 12 | 0.050 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2022 | 108 | 0.050 |
Why?
|
| Polymorphism, Genetic | 2 | 2009 | 4328 | 0.050 |
Why?
|
| Postoperative Complications | 7 | 2018 | 15295 | 0.050 |
Why?
|
| Latin America | 2 | 2018 | 380 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 1 | 2008 | 2700 | 0.050 |
Why?
|
| Myelin P2 Protein | 1 | 2000 | 20 | 0.050 |
Why?
|
| Mortality | 4 | 2018 | 2864 | 0.050 |
Why?
|
| Musculoskeletal Diseases | 1 | 2007 | 581 | 0.050 |
Why?
|
| Continuity of Patient Care | 1 | 2008 | 1049 | 0.050 |
Why?
|
| Drug Monitoring | 2 | 2018 | 956 | 0.050 |
Why?
|
| Neoplasms | 2 | 2021 | 21693 | 0.050 |
Why?
|
| Fibrosis | 2 | 2018 | 2029 | 0.050 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2021 | 144 | 0.050 |
Why?
|
| Chemokine CCL2 | 1 | 2003 | 619 | 0.050 |
Why?
|
| Thallium Radioisotopes | 2 | 1997 | 139 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2009 | 2441 | 0.050 |
Why?
|
| Pericarditis, Tuberculous | 1 | 1979 | 6 | 0.050 |
Why?
|
| Tuberculosis, Cardiovascular | 1 | 1979 | 9 | 0.050 |
Why?
|
| Serum Amyloid A Protein | 1 | 2000 | 121 | 0.040 |
Why?
|
| Patient Admission | 2 | 2012 | 1380 | 0.040 |
Why?
|
| Serum Albumin | 1 | 2003 | 675 | 0.040 |
Why?
|
| Analgesics | 1 | 2007 | 1040 | 0.040 |
Why?
|
| Value of Life | 1 | 2000 | 97 | 0.040 |
Why?
|
| Public Opinion | 1 | 2004 | 477 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2019 | 15520 | 0.040 |
Why?
|
| Cineangiography | 1 | 1999 | 124 | 0.040 |
Why?
|
| Seizures, Febrile | 1 | 2001 | 111 | 0.040 |
Why?
|
| Mutation | 3 | 2021 | 29786 | 0.040 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2021 | 241 | 0.040 |
Why?
|
| Technetium Tc 99m Sestamibi | 2 | 1997 | 177 | 0.040 |
Why?
|
| North America | 2 | 2001 | 1249 | 0.040 |
Why?
|
| Atherosclerosis | 3 | 2021 | 3444 | 0.040 |
Why?
|
| Regional Blood Flow | 5 | 2004 | 1525 | 0.040 |
Why?
|
| South America | 1 | 1999 | 181 | 0.040 |
Why?
|
| Decision Making, Computer-Assisted | 2 | 1997 | 150 | 0.040 |
Why?
|
| Genetic Variation | 2 | 2015 | 6542 | 0.040 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2000 | 170 | 0.040 |
Why?
|
| Adenosine Diphosphate | 2 | 2011 | 425 | 0.040 |
Why?
|
| Calcinosis | 2 | 2005 | 1499 | 0.040 |
Why?
|
| Geography | 1 | 2001 | 669 | 0.040 |
Why?
|
| Heart Auscultation | 1 | 1978 | 37 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2007 | 3480 | 0.040 |
Why?
|
| Statistics, Nonparametric | 4 | 2008 | 2887 | 0.040 |
Why?
|
| Equipment Design | 2 | 2007 | 3582 | 0.040 |
Why?
|
| Camphor | 1 | 1978 | 9 | 0.040 |
Why?
|
| Heart Murmurs | 1 | 1978 | 94 | 0.040 |
Why?
|
| Contrast Media | 3 | 2001 | 5300 | 0.040 |
Why?
|
| Linoleic Acid | 1 | 2019 | 157 | 0.040 |
Why?
|
| Lower Extremity | 1 | 2006 | 1158 | 0.040 |
Why?
|
| Receptors, LDL | 1 | 2021 | 476 | 0.040 |
Why?
|
| Cardiac Tamponade | 1 | 1979 | 173 | 0.040 |
Why?
|
| Electrophysiology | 3 | 1995 | 1308 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2004 | 1608 | 0.040 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2023 | 546 | 0.040 |
Why?
|
| Arachidonic Acid | 1 | 2019 | 434 | 0.040 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2019 | 162 | 0.040 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2012 | 3047 | 0.040 |
Why?
|
| Ion Channels | 3 | 1984 | 1056 | 0.040 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 1 | 2019 | 124 | 0.040 |
Why?
|
| Apolipoproteins | 1 | 2000 | 317 | 0.040 |
Why?
|
| Hemorheology | 1 | 1997 | 145 | 0.040 |
Why?
|
| Information Services | 1 | 1999 | 244 | 0.040 |
Why?
|
| Aortic Rupture | 2 | 2006 | 312 | 0.040 |
Why?
|
| Pericardial Effusion | 1 | 1979 | 247 | 0.040 |
Why?
|
| Policy | 1 | 2021 | 508 | 0.040 |
Why?
|
| Serine | 1 | 2021 | 826 | 0.040 |
Why?
|
| Oximetry | 1 | 1980 | 471 | 0.040 |
Why?
|
| Graft Occlusion, Vascular | 2 | 2012 | 549 | 0.040 |
Why?
|
| Random Allocation | 4 | 1989 | 2428 | 0.040 |
Why?
|
| Markov Chains | 2 | 2012 | 969 | 0.040 |
Why?
|
| Poisoning | 1 | 1978 | 249 | 0.040 |
Why?
|
| Calcium Channels | 1 | 2000 | 622 | 0.040 |
Why?
|
| Germany | 1 | 2019 | 862 | 0.040 |
Why?
|
| Body Mass Index | 3 | 2024 | 12720 | 0.040 |
Why?
|
| Cardiomegaly | 1 | 1979 | 620 | 0.030 |
Why?
|
| Cardiopulmonary Bypass | 2 | 1996 | 1066 | 0.030 |
Why?
|
| Electrocardiography, Ambulatory | 3 | 1994 | 585 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 2016 | 380 | 0.030 |
Why?
|
| Retreatment | 2 | 2011 | 610 | 0.030 |
Why?
|
| Hyperparathyroidism | 1 | 1977 | 339 | 0.030 |
Why?
|
| Public Policy | 2 | 2012 | 572 | 0.030 |
Why?
|
| Systole | 2 | 2016 | 958 | 0.030 |
Why?
|
| Curriculum | 1 | 2008 | 3605 | 0.030 |
Why?
|
| Disease | 1 | 2021 | 680 | 0.030 |
Why?
|
| Dyspnea | 1 | 2023 | 1303 | 0.030 |
Why?
|
| Death | 1 | 2020 | 678 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2023 | 2617 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 3 | 2008 | 1681 | 0.030 |
Why?
|
| Sick Sinus Syndrome | 2 | 1993 | 44 | 0.030 |
Why?
|
| Heart | 6 | 1987 | 4464 | 0.030 |
Why?
|
| Vasodilator Agents | 2 | 1998 | 976 | 0.030 |
Why?
|
| Potassium | 3 | 1990 | 1336 | 0.030 |
Why?
|
| Chest Pain | 2 | 2002 | 1114 | 0.030 |
Why?
|
| Pilot Projects | 3 | 2017 | 8319 | 0.030 |
Why?
|
| Prevalence | 6 | 2008 | 15221 | 0.030 |
Why?
|
| Iliac Artery | 2 | 2006 | 364 | 0.030 |
Why?
|
| Reference Values | 3 | 2003 | 4982 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2008 | 3209 | 0.030 |
Why?
|
| Carrier Proteins | 2 | 2014 | 5023 | 0.030 |
Why?
|
| Postoperative Care | 2 | 2002 | 1487 | 0.030 |
Why?
|
| Health Planning Guidelines | 2 | 2006 | 163 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2020 | 2634 | 0.030 |
Why?
|
| Glycine | 1 | 1997 | 671 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2016 | 683 | 0.030 |
Why?
|
| Causality | 2 | 2016 | 1275 | 0.030 |
Why?
|
| Renal Artery | 2 | 2006 | 399 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2008 | 3338 | 0.030 |
Why?
|
| United Nations | 1 | 2014 | 165 | 0.030 |
Why?
|
| Cardiac Output | 2 | 1988 | 854 | 0.030 |
Why?
|
| Aneurysm | 2 | 2006 | 339 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 1994 | 379 | 0.030 |
Why?
|
| Heart-Assist Devices | 1 | 2004 | 1195 | 0.030 |
Why?
|
| Achievement | 1 | 2015 | 291 | 0.030 |
Why?
|
| Pindolol | 1 | 1993 | 32 | 0.030 |
Why?
|
| Nausea | 1 | 2016 | 674 | 0.030 |
Why?
|
| Probability | 2 | 2010 | 2506 | 0.030 |
Why?
|
| Sample Size | 1 | 1996 | 845 | 0.030 |
Why?
|
| Somatoform Disorders | 1 | 1996 | 423 | 0.030 |
Why?
|
| Piperidines | 2 | 1997 | 1602 | 0.030 |
Why?
|
| Aorta, Abdominal | 2 | 2006 | 646 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2021 | 2682 | 0.030 |
Why?
|
| Dogs | 5 | 1987 | 3912 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2013 | 265 | 0.030 |
Why?
|
| Foundations | 1 | 2012 | 94 | 0.030 |
Why?
|
| Intraoperative Period | 2 | 2003 | 520 | 0.030 |
Why?
|
| Anticholesteremic Agents | 1 | 2000 | 979 | 0.030 |
Why?
|
| Organizational Objectives | 1 | 2014 | 438 | 0.030 |
Why?
|
| Dilatation, Pathologic | 1 | 1994 | 520 | 0.030 |
Why?
|
| MEDLINE | 1 | 1992 | 125 | 0.030 |
Why?
|
| Developmental Disabilities | 1 | 2001 | 1456 | 0.030 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 2 | 2006 | 493 | 0.030 |
Why?
|
| Accreditation | 1 | 2015 | 451 | 0.030 |
Why?
|
| Calcium | 3 | 1983 | 5755 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2003 | 2219 | 0.030 |
Why?
|
| Pain | 1 | 2007 | 4987 | 0.030 |
Why?
|
| Protein Binding | 2 | 2003 | 9384 | 0.020 |
Why?
|
| Area Under Curve | 2 | 2008 | 1655 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 1996 | 1254 | 0.020 |
Why?
|
| Platelet Activating Factor | 1 | 2011 | 149 | 0.020 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2012 | 194 | 0.020 |
Why?
|
| Organizational Culture | 1 | 2015 | 510 | 0.020 |
Why?
|
| Organ Size | 1 | 2016 | 2251 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2016 | 1793 | 0.020 |
Why?
|
| Analysis of Variance | 3 | 2006 | 6366 | 0.020 |
Why?
|
| Shock, Cardiogenic | 3 | 2010 | 688 | 0.020 |
Why?
|
| Arrhythmia, Sinus | 2 | 1989 | 56 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2021 | 2575 | 0.020 |
Why?
|
| Leg | 2 | 2006 | 1116 | 0.020 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2016 | 857 | 0.020 |
Why?
|
| Blood Transfusion | 2 | 2007 | 1301 | 0.020 |
Why?
|
| Neutrophils | 1 | 2023 | 3721 | 0.020 |
Why?
|
| Peer Review | 1 | 2012 | 209 | 0.020 |
Why?
|
| Histones | 1 | 2021 | 2599 | 0.020 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2018 | 990 | 0.020 |
Why?
|
| Quality of Life | 5 | 2017 | 12803 | 0.020 |
Why?
|
| Diagnostic Imaging | 3 | 2012 | 3508 | 0.020 |
Why?
|
| Platelet Adhesiveness | 1 | 2010 | 161 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2000 | 2850 | 0.020 |
Why?
|
| Polypharmacy | 1 | 2012 | 294 | 0.020 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2012 | 269 | 0.020 |
Why?
|
| Emergency Treatment | 2 | 2004 | 517 | 0.020 |
Why?
|
| Angiocardiography | 2 | 1980 | 162 | 0.020 |
Why?
|
| Specialization | 1 | 1994 | 776 | 0.020 |
Why?
|
| Angiography | 3 | 2004 | 1639 | 0.020 |
Why?
|
| Infant | 4 | 2021 | 35134 | 0.020 |
Why?
|
| Cerebrovascular Disorders | 1 | 1996 | 1504 | 0.020 |
Why?
|
| Cardiomyopathies | 3 | 2006 | 1912 | 0.020 |
Why?
|
| Italy | 1 | 2011 | 832 | 0.020 |
Why?
|
| Biotransformation | 1 | 2009 | 168 | 0.020 |
Why?
|
| Microsomes, Liver | 1 | 2009 | 173 | 0.020 |
Why?
|
| Pregnancy Complications, Cardiovascular | 2 | 2003 | 500 | 0.020 |
Why?
|
| Deductibles and Coinsurance | 1 | 2011 | 316 | 0.020 |
Why?
|
| Aortic Aneurysm | 1 | 1994 | 644 | 0.020 |
Why?
|
| Choice Behavior | 1 | 2015 | 802 | 0.020 |
Why?
|
| Mitral Valve Insufficiency | 1 | 1978 | 1421 | 0.020 |
Why?
|
| Actuarial Analysis | 1 | 1988 | 378 | 0.020 |
Why?
|
| Oxygen | 1 | 1980 | 4189 | 0.020 |
Why?
|
| Atrioventricular Node | 2 | 2006 | 182 | 0.020 |
Why?
|
| Procainamide | 2 | 1985 | 61 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2024 | 17445 | 0.020 |
Why?
|
| Skin Tests | 1 | 1990 | 613 | 0.020 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2014 | 964 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 1990 | 1095 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2024 | 13988 | 0.020 |
Why?
|
| Overweight | 1 | 2019 | 2371 | 0.020 |
Why?
|
| Moricizine | 1 | 1987 | 4 | 0.020 |
Why?
|
| Checklist | 1 | 2015 | 833 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2000 | 3706 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 2003 | 4369 | 0.020 |
Why?
|
| Microcirculation | 2 | 2002 | 1287 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2013 | 2297 | 0.020 |
Why?
|
| Genome, Human | 1 | 2021 | 4420 | 0.020 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 1988 | 264 | 0.020 |
Why?
|
| Phenytoin | 2 | 1985 | 197 | 0.020 |
Why?
|
| Hypolipidemic Agents | 2 | 2002 | 604 | 0.020 |
Why?
|
| Ischemia | 2 | 2006 | 1907 | 0.020 |
Why?
|
| Blood Urea Nitrogen | 1 | 1987 | 191 | 0.020 |
Why?
|
| Biological Availability | 2 | 1985 | 397 | 0.020 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2011 | 342 | 0.020 |
Why?
|
| Critical Care | 3 | 2012 | 2647 | 0.020 |
Why?
|
| Prosthesis Failure | 1 | 2012 | 1206 | 0.020 |
Why?
|
| Age Distribution | 1 | 2013 | 2902 | 0.020 |
Why?
|
| Aftercare | 1 | 2013 | 870 | 0.020 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 2 | 2003 | 137 | 0.020 |
Why?
|
| Infusions, Parenteral | 3 | 1985 | 419 | 0.020 |
Why?
|
| Propensity Score | 1 | 2013 | 1781 | 0.020 |
Why?
|
| Reoperation | 1 | 1996 | 4201 | 0.020 |
Why?
|
| New York | 2 | 2002 | 886 | 0.020 |
Why?
|
| Aortic Aneurysm, Abdominal | 2 | 2006 | 1186 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 1987 | 919 | 0.020 |
Why?
|
| Observer Variation | 1 | 2012 | 2593 | 0.020 |
Why?
|
| Atrial Function | 1 | 2006 | 107 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2015 | 2488 | 0.020 |
Why?
|
| Models, Econometric | 1 | 2007 | 218 | 0.020 |
Why?
|
| Femoral Vein | 1 | 2007 | 159 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 1987 | 683 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2012 | 1683 | 0.020 |
Why?
|
| Organotechnetium Compounds | 1 | 1986 | 137 | 0.020 |
Why?
|
| Isosorbide | 1 | 1985 | 3 | 0.020 |
Why?
|
| Prescription Fees | 1 | 2007 | 146 | 0.020 |
Why?
|
| Nadolol | 1 | 1985 | 30 | 0.020 |
Why?
|
| Technetium | 1 | 1986 | 334 | 0.020 |
Why?
|
| Hospital Costs | 1 | 2012 | 985 | 0.020 |
Why?
|
| Terminal Care | 3 | 2002 | 1694 | 0.020 |
Why?
|
| Carotid Sinus | 1 | 1985 | 45 | 0.020 |
Why?
|
| Body Surface Potential Mapping | 2 | 1997 | 238 | 0.020 |
Why?
|
| Motivation | 1 | 2015 | 1971 | 0.020 |
Why?
|
| Renal Artery Obstruction | 1 | 2006 | 248 | 0.020 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2015 | 1209 | 0.020 |
Why?
|
| Timolol | 1 | 1984 | 52 | 0.020 |
Why?
|
| Administrative Personnel | 1 | 2006 | 187 | 0.020 |
Why?
|
| Thrombectomy | 1 | 2009 | 680 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2012 | 2453 | 0.020 |
Why?
|
| Codes of Ethics | 1 | 2004 | 62 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2018 | 21747 | 0.020 |
Why?
|
| Heart Valves | 1 | 2006 | 291 | 0.020 |
Why?
|
| Thoracic Surgery | 1 | 2011 | 719 | 0.020 |
Why?
|
| Mitral Valve Prolapse | 1 | 2006 | 231 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2008 | 11725 | 0.020 |
Why?
|
| Health Services Research | 1 | 2012 | 1836 | 0.020 |
Why?
|
| Parasympathetic Nervous System | 1 | 1985 | 141 | 0.020 |
Why?
|
| Diagnosis-Related Groups | 1 | 2006 | 455 | 0.020 |
Why?
|
| Financing, Personal | 1 | 2007 | 308 | 0.010 |
Why?
|
| Tachycardia, Ectopic Junctional | 1 | 2003 | 19 | 0.010 |
Why?
|
| Child, Preschool | 4 | 2014 | 41005 | 0.010 |
Why?
|
| Endocardium | 1 | 1985 | 263 | 0.010 |
Why?
|
| Tachycardia, Paroxysmal | 1 | 2003 | 31 | 0.010 |
Why?
|
| Mitral Valve Stenosis | 1 | 2006 | 376 | 0.010 |
Why?
|
| Tachycardia, Sinus | 1 | 2003 | 42 | 0.010 |
Why?
|
| Cheek | 1 | 1983 | 63 | 0.010 |
Why?
|
| Popliteal Artery | 1 | 2006 | 317 | 0.010 |
Why?
|
| Oxidative Stress | 2 | 2006 | 3084 | 0.010 |
Why?
|
| Marketing of Health Services | 1 | 2004 | 153 | 0.010 |
Why?
|
| Tachycardia, Ectopic Atrial | 1 | 2003 | 66 | 0.010 |
Why?
|
| Counterpulsation | 1 | 2003 | 19 | 0.010 |
Why?
|
| Mental Competency | 1 | 2004 | 176 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2016 | 35424 | 0.010 |
Why?
|
| Equipment Failure | 1 | 1985 | 578 | 0.010 |
Why?
|
| Arteriosclerosis | 1 | 1988 | 1092 | 0.010 |
Why?
|
| Life Expectancy | 1 | 2009 | 1184 | 0.010 |
Why?
|
| Fractals | 1 | 2003 | 123 | 0.010 |
Why?
|
| Heart Arrest, Induced | 1 | 2004 | 355 | 0.010 |
Why?
|
| Thyroid Diseases | 1 | 1986 | 379 | 0.010 |
Why?
|
| Delayed-Action Preparations | 1 | 2006 | 968 | 0.010 |
Why?
|
| Action Potentials | 2 | 1980 | 1806 | 0.010 |
Why?
|
| Coronary Vasospasm | 1 | 1983 | 88 | 0.010 |
Why?
|
| Medical Staff, Hospital | 1 | 2006 | 601 | 0.010 |
Why?
|
| Endocarditis, Bacterial | 1 | 2006 | 455 | 0.010 |
Why?
|
| Disease Progression | 1 | 2019 | 13285 | 0.010 |
Why?
|
| Documentation | 1 | 1988 | 871 | 0.010 |
Why?
|
| Sympathetic Nervous System | 1 | 1985 | 513 | 0.010 |
Why?
|
| Disease Models, Animal | 2 | 1999 | 18034 | 0.010 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2006 | 579 | 0.010 |
Why?
|
| Organometallic Compounds | 1 | 1986 | 665 | 0.010 |
Why?
|
| Expert Testimony | 1 | 2004 | 356 | 0.010 |
Why?
|
| Platelet Count | 1 | 2004 | 780 | 0.010 |
Why?
|
| Directive Counseling | 1 | 2003 | 166 | 0.010 |
Why?
|
| Europe, Eastern | 1 | 2001 | 75 | 0.010 |
Why?
|
| Case Management | 1 | 2003 | 286 | 0.010 |
Why?
|
| Femoral Artery | 1 | 2006 | 845 | 0.010 |
Why?
|
| Receptors, Angiotensin | 1 | 2001 | 142 | 0.010 |
Why?
|
| Inpatients | 1 | 2013 | 2518 | 0.010 |
Why?
|
| Crohn Disease | 1 | 1994 | 2304 | 0.010 |
Why?
|
| Disopyramide | 1 | 1980 | 16 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2010 | 4222 | 0.010 |
Why?
|
| Injections, Intra-Arterial | 1 | 2000 | 193 | 0.010 |
Why?
|
| Pyrrolidines | 1 | 2003 | 342 | 0.010 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 1987 | 851 | 0.010 |
Why?
|
| Patient Care Team | 1 | 2012 | 2531 | 0.010 |
Why?
|
| Nitriles | 1 | 1986 | 955 | 0.010 |
Why?
|
| Alanine | 1 | 2003 | 572 | 0.010 |
Why?
|
| Truth Disclosure | 1 | 2004 | 436 | 0.010 |
Why?
|
| Tomography, Emission-Computed | 1 | 2003 | 1144 | 0.010 |
Why?
|
| Rest | 1 | 1985 | 901 | 0.010 |
Why?
|
| Research Support as Topic | 1 | 2004 | 705 | 0.010 |
Why?
|
| Cineradiography | 1 | 1979 | 24 | 0.010 |
Why?
|
| Equipment and Supplies | 1 | 2002 | 281 | 0.010 |
Why?
|
| Spasm | 1 | 1980 | 121 | 0.010 |
Why?
|
| Kinetics | 2 | 1985 | 6476 | 0.010 |
Why?
|
| Electric Stimulation | 1 | 1985 | 1767 | 0.010 |
Why?
|
| Rheology | 1 | 2000 | 345 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 1994 | 3922 | 0.010 |
Why?
|
| Demography | 1 | 2004 | 1656 | 0.010 |
Why?
|
| Research Personnel | 1 | 2004 | 573 | 0.010 |
Why?
|
| Syncope | 1 | 2002 | 429 | 0.010 |
Why?
|
| Hospitals | 2 | 2004 | 3954 | 0.010 |
Why?
|
| Guinea Pigs | 1 | 1980 | 1386 | 0.010 |
Why?
|
| Linear Models | 1 | 2009 | 5952 | 0.010 |
Why?
|
| Child | 4 | 2014 | 77708 | 0.010 |
Why?
|
| Anthropometry | 1 | 2003 | 1350 | 0.010 |
Why?
|
| Pregnancy | 3 | 2006 | 29144 | 0.010 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2000 | 300 | 0.010 |
Why?
|
| Antihypertensive Agents | 1 | 2008 | 2047 | 0.010 |
Why?
|
| Ischemic Preconditioning, Myocardial | 1 | 1998 | 67 | 0.010 |
Why?
|
| Informed Consent | 1 | 2004 | 995 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2001 | 1799 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2009 | 8437 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 2003 | 1680 | 0.010 |
Why?
|
| P-Selectin | 1 | 2000 | 601 | 0.010 |
Why?
|
| Exercise Tolerance | 1 | 2002 | 768 | 0.010 |
Why?
|
| Pulmonary Circulation | 1 | 1980 | 739 | 0.010 |
Why?
|
| Diabetic Angiopathies | 1 | 2002 | 818 | 0.010 |
Why?
|
| Respiration Disorders | 1 | 1980 | 371 | 0.010 |
Why?
|
| Hormone Replacement Therapy | 1 | 2003 | 745 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 2003 | 25628 | 0.010 |
Why?
|
| Vascular Surgical Procedures | 1 | 2006 | 1476 | 0.010 |
Why?
|
| Electric Stimulation Therapy | 1 | 2003 | 605 | 0.010 |
Why?
|
| Age of Onset | 1 | 2003 | 3270 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 1980 | 1472 | 0.010 |
Why?
|
| Intestines | 1 | 2006 | 1924 | 0.010 |
Why?
|
| Inflammation | 1 | 2016 | 10636 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 2002 | 921 | 0.010 |
Why?
|
| Hypoglycemic Agents | 1 | 2008 | 2873 | 0.010 |
Why?
|
| Publishing | 1 | 2003 | 833 | 0.010 |
Why?
|
| Drug Hypersensitivity | 2 | 1984 | 884 | 0.010 |
Why?
|
| Stress, Mechanical | 1 | 2000 | 1686 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2018 | 11126 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2009 | 6254 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 2008 | 2535 | 0.010 |
Why?
|
| Heart Block | 1 | 1977 | 410 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2002 | 1917 | 0.010 |
Why?
|
| Patients | 1 | 2001 | 900 | 0.010 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2006 | 2026 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2004 | 2866 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2006 | 4458 | 0.010 |
Why?
|
| Autoimmune Diseases | 1 | 1986 | 2133 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 1980 | 2027 | 0.010 |
Why?
|
| Massachusetts | 2 | 2002 | 8662 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 13104 | 0.010 |
Why?
|
| Ouabain | 2 | 1984 | 264 | 0.010 |
Why?
|
| Insulin | 1 | 2008 | 6582 | 0.010 |
Why?
|
| Texas | 1 | 1994 | 391 | 0.010 |
Why?
|
| Renal Dialysis | 2 | 1984 | 1783 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2006 | 5984 | 0.010 |
Why?
|
| Lung Diseases | 1 | 2003 | 1887 | 0.010 |
Why?
|
| Women's Health | 1 | 2002 | 2034 | 0.010 |
Why?
|
| Refractory Period, Electrophysiological | 2 | 1987 | 39 | 0.010 |
Why?
|
| Kidney Calculi | 1 | 1977 | 465 | 0.010 |
Why?
|
| Capsules | 1 | 1993 | 196 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2002 | 5077 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 2003 | 2897 | 0.010 |
Why?
|
| Arterial Occlusive Diseases | 2 | 1987 | 793 | 0.010 |
Why?
|
| Medical Records | 1 | 1997 | 1413 | 0.010 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 2 | 1984 | 494 | 0.010 |
Why?
|
| Lipids | 1 | 2003 | 3307 | 0.010 |
Why?
|
| Exercise | 2 | 2002 | 5615 | 0.010 |
Why?
|
| Critical Illness | 1 | 2003 | 2670 | 0.010 |
Why?
|
| Heart Transplantation | 1 | 2002 | 3112 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 1986 | 10183 | 0.010 |
Why?
|
| Placebos | 1 | 1993 | 1676 | 0.000 |
Why?
|
| Heart Septum | 1 | 1989 | 312 | 0.000 |
Why?
|
| Medicare | 1 | 2006 | 6566 | 0.000 |
Why?
|
| Mass Screening | 1 | 2003 | 5255 | 0.000 |
Why?
|
| Internal Medicine | 1 | 1994 | 1009 | 0.000 |
Why?
|
| Milrinone | 1 | 1987 | 84 | 0.000 |
Why?
|
| Microsomes | 1 | 1986 | 257 | 0.000 |
Why?
|
| Thyroglobulin | 1 | 1986 | 114 | 0.000 |
Why?
|
| Electricity | 1 | 1986 | 182 | 0.000 |
Why?
|
| Drug Prescriptions | 1 | 1994 | 1637 | 0.000 |
Why?
|
| Hemoperfusion | 1 | 1984 | 14 | 0.000 |
Why?
|
| Cholestyramine Resin | 1 | 1984 | 24 | 0.000 |
Why?
|
| Neural Pathways | 2 | 1987 | 2973 | 0.000 |
Why?
|
| Purkinje Fibers | 1 | 1984 | 32 | 0.000 |
Why?
|
| Deslanoside | 1 | 1984 | 1 | 0.000 |
Why?
|
| Saphenous Vein | 1 | 1988 | 532 | 0.000 |
Why?
|
| Strophanthidin | 1 | 1984 | 15 | 0.000 |
Why?
|
| Lanatosides | 1 | 1984 | 6 | 0.000 |
Why?
|
| Digitoxin | 1 | 1984 | 22 | 0.000 |
Why?
|
| Ambulatory Care | 2 | 1987 | 2708 | 0.000 |
Why?
|
| Cardiac Complexes, Premature | 1 | 1983 | 64 | 0.000 |
Why?
|
| Sleep Deprivation | 1 | 1990 | 832 | 0.000 |
Why?
|
| Hypokalemia | 1 | 1984 | 153 | 0.000 |
Why?
|
| Eating | 1 | 1990 | 1536 | 0.000 |
Why?
|
| Electrolytes | 1 | 1984 | 282 | 0.000 |
Why?
|
| Guanylate Cyclase | 1 | 1983 | 201 | 0.000 |
Why?
|
| Intestinal Absorption | 1 | 1984 | 420 | 0.000 |
Why?
|
| Perfusion | 1 | 1987 | 1360 | 0.000 |
Why?
|
| Sulfhydryl Compounds | 1 | 1983 | 298 | 0.000 |
Why?
|
| Endocrine System Diseases | 1 | 1984 | 248 | 0.000 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1986 | 1475 | 0.000 |
Why?
|
| Norepinephrine | 1 | 1984 | 909 | 0.000 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 1984 | 360 | 0.000 |
Why?
|
| Saliva | 1 | 1984 | 809 | 0.000 |
Why?
|
| Nitrogen | 1 | 1980 | 344 | 0.000 |
Why?
|
| Drug Synergism | 1 | 1983 | 1797 | 0.000 |
Why?
|
| Thyroid Gland | 1 | 1986 | 1173 | 0.000 |
Why?
|
| Oxygen Consumption | 1 | 1985 | 1868 | 0.000 |
Why?
|
| Oxidation-Reduction | 1 | 1983 | 2184 | 0.000 |
Why?
|
| Autoantibodies | 1 | 1986 | 2036 | 0.000 |
Why?
|
| Enzyme Activation | 1 | 1983 | 3702 | 0.000 |
Why?
|
| Vision Disorders | 1 | 1984 | 1058 | 0.000 |
Why?
|
| Vasodilation | 1 | 1980 | 944 | 0.000 |
Why?
|
| Muscle Contraction | 1 | 1981 | 1235 | 0.000 |
Why?
|
| Antibodies | 1 | 1984 | 2460 | 0.000 |
Why?
|
| Flow Cytometry | 1 | 1986 | 5974 | 0.000 |
Why?
|
| Stress, Psychological | 1 | 1990 | 4244 | 0.000 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 1981 | 1504 | 0.000 |
Why?
|
| Erythrocytes | 1 | 1984 | 2455 | 0.000 |
Why?
|
| Nervous System Diseases | 1 | 1984 | 1622 | 0.000 |
Why?
|
| Immunoglobulin G | 1 | 1984 | 4561 | 0.000 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1975 | 1375 | 0.000 |
Why?
|